Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis: a retrospective cohort study.

De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, Verleden GM, Verleden SE, Wuyts WA.

Eur Respir J. 2020 Jan 16. pii: 1901983. doi: 10.1183/13993003.01983-2019. [Epub ahead of print] No abstract available.

PMID:
31949120
2.

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.

Rinciog C, Diamantopoulos A, Gentilini A, Bondue B, Dahlqvist C, Froidure A, Wuyts WA, Soulard S.

Pharmacoecon Open. 2020 Jan 14. doi: 10.1007/s41669-019-00191-w. [Epub ahead of print]

3.

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.

Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G.

BMC Pulm Med. 2020 Jan 8;20(1):3. doi: 10.1186/s12890-019-1030-4.

4.

Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.

Wuyts WA, Wijsenbeek M, Bondue B, Bouros D, Bresser P, Robalo Cordeiro C, Hilberg O, Magnusson J, Manali ED, Morais A, Papiris S, Shaker S, Veltkamp M, Bendstrup E.

Respiration. 2020;99(1):73-82. doi: 10.1159/000504763. Epub 2019 Dec 12. Review.

5.

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.

Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, Maddens S, Lee YC, Kirchgaessler KU, Bartley K, Bondue B.

Respir Res. 2019 Oct 24;20(1):231. doi: 10.1186/s12931-019-1182-z.

6.

Transcriptional regulatory model of fibrosis progression in the human lung.

McDonough JE, Ahangari F, Li Q, Jain S, Verleden SE, Herazo-Maya J, Vukmirovic M, DeIuliis G, Tzouvelekis A, Tanabe N, Chu F, Yan X, Verschakelen J, Homer RJ, Manatakis DV, Zhang J, Ding J, Maes K, De Sadeleer L, Vos R, Neyrinck A, Benos PV, Bar-Joseph Z, Tantin D, Hogg JC, Vanaudenaerde BM, Wuyts WA, Kaminski N.

JCI Insight. 2019 Nov 14;4(22). pii: 131597. doi: 10.1172/jci.insight.131597.

7.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.

Adv Ther. 2019 Nov;36(11):3059-3070. doi: 10.1007/s12325-019-01093-3. Epub 2019 Sep 29.

8.

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU.

Lancet Respir Med. 2019 Sep;7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4. Epub 2019 Aug 12.

PMID:
31416769
9.

Granulomatous lung disease in two workers making light bulbs.

Ronsmans S, Verbeken EK, Adams E, Keirsbilck S, Yserbyt J, Wuyts WA, Swennen R, Hoet PH, Nemery B.

Am J Ind Med. 2019 Oct;62(10):908-913. doi: 10.1002/ajim.23030. Epub 2019 Jul 26.

PMID:
31347732
10.

Outcome of lung transplantation in non-idiopathic pulmonary fibrosis interstitial lung disease.

Bode H, Verleden SE, Wuyts WA, Yserbyt J, Verleden GM, Vos R.

Clin Transplant. 2019 Oct;33(10):e13661. doi: 10.1111/ctr.13661. Epub 2019 Aug 6.

PMID:
31286560
11.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

12.

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.

Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, Stauffer JL, Morgenthien E, Chou W, Limb SL, Noble PW.

Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24.

13.

The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis.

Cottin V, Annesi-Maesano I, Günther A, Galvin L, Kreuter M, Powell P, Prasse A, Reynolds G, Richeldi L, Spagnolo P, Valenzuela C, Wijsenbeek M, Wuyts WA, Crestani B; Ariane-IPF Clinical Research Collaboration consortium.

Eur Respir J. 2019 May 23;53(5). pii: 1900539. doi: 10.1183/13993003.00539-2019. Print 2019 May. No abstract available.

PMID:
31123022
14.

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.

Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW.

Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2.

15.

Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study.

De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, Verleden GM, Wuyts WA.

J Clin Med. 2018 Dec 21;8(1). pii: E14. doi: 10.3390/jcm8010014.

16.

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.

Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, Maddens S, Kirchgaessler KU, Bartley K, Bondue B.

BMJ Open Respir Res. 2018 Nov 21;5(1):e000331. doi: 10.1136/bmjresp-2018-000331. eCollection 2018.

17.

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.

van Cleemput J, Sonaglioni A, Wuyts WA, Bengus M, Stauffer JL, Harari S.

Adv Ther. 2019 Feb;36(2):298-317. doi: 10.1007/s12325-018-0857-z. Epub 2018 Dec 15. Review.

18.

Determinants of survival in lung transplantation patients with idiopathic pulmonary fibrosis: a retrospective cohort study.

Tuyls S, Verleden SE, Wuyts WA, Yserbyt J, Vos R, Verleden GM.

Transpl Int. 2019 Apr;32(4):399-409. doi: 10.1111/tri.13382. Epub 2018 Dec 21.

PMID:
30488486
19.

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis.

McDonough JE, Kaminski N, Thienpont B, Hogg JC, Vanaudenaerde BM, Wuyts WA.

Thorax. 2019 Feb;74(2):132-140. doi: 10.1136/thoraxjnl-2018-211929. Epub 2018 Oct 26.

20.

Response.

De Sadeleer LJ, Wuyts WA.

Chest. 2018 Sep;154(3):714-715. doi: 10.1016/j.chest.2018.06.020. No abstract available.

PMID:
30195350
21.

BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis.

Prasse A, Binder H, Schupp JC, Kayser G, Bargagli E, Jaeger B, Hess M, Rittinghausen S, Vuga L, Lynn H, Violette S, Jung B, Quast K, Vanaudenaerde B, Xu Y, Hohlfeld JM, Krug N, Herazo-Maya JD, Rottoli P, Wuyts WA, Kaminski N.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):622-630. doi: 10.1164/rccm.201712-2551OC.

PMID:
30141961
22.

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.

Vancheri C, Kreuter M, Richeldi L, Quaresma M, Stowasser S, Wuyts WA.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1105-1106. doi: 10.1164/rccm.201806-1116LE. No abstract available.

PMID:
30025211
23.

Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series.

Vos R, Wuyts WA, Gheysens O, Goffin KE, Schaevers V, Verleden SE, Van Herck A, Sacreas A, Heigl T, McDonough JE, Yserbyt J, Godinas L, Dupont LJ, Neyrinck AP, Van Raemdonck DE, Verbeken EK, Vanaudenaerde BM, Verleden GM.

Am J Transplant. 2018 Dec;18(12):3045-3059. doi: 10.1111/ajt.15019. Epub 2018 Aug 17.

24.

A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis.

McDonough JE, Martens DS, Tanabe N, Ahangari F, Verleden SE, Maes K, Verleden GM, Kaminski N, Hogg JC, Nawrot TS, Wuyts WA, Vanaudenaerde BM.

Respir Res. 2018 Jul 9;19(1):132. doi: 10.1186/s12931-018-0838-4.

25.

Clinical behaviour of patients exposed to organic dust and diagnosed with idiopathic pulmonary fibrosis.

De Sadeleer LJ, Verleden SE, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, Nemery B, Verleden GM, Hermans F, Vanaudenaerde BM, Wuyts WA.

Respirology. 2018 Dec;23(12):1160-1165. doi: 10.1111/resp.13342. Epub 2018 Jun 13.

PMID:
29897160
26.

The aging lung: tissue telomere shortening in health and disease.

Everaerts S, Lammertyn EJ, Martens DS, De Sadeleer LJ, Maes K, van Batenburg AA, Goldschmeding R, van Moorsel CHM, Dupont LJ, Wuyts WA, Vos R, Gayan-Ramirez G, Kaminski N, Hogg JC, Janssens W, Verleden GM, Nawrot TS, Verleden SE, McDonough JE, Vanaudenaerde BM.

Respir Res. 2018 May 11;19(1):95. doi: 10.1186/s12931-018-0794-z.

27.

Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases: A Retrospective Observational Study of 938 Cases.

De Sadeleer LJ, Meert C, Yserbyt J, Slabbynck H, Verschakelen JA, Verbeken EK, Weynand B, De Langhe E, Lenaerts JL, Nemery B, Van Raemdonck D, Verleden GM, Wells AU, Wuyts WA.

Chest. 2018 Jun;153(6):1416-1423. doi: 10.1016/j.chest.2018.03.026. Epub 2018 Mar 30.

PMID:
29608882
28.

Multiple Solid Organ Transplantation in Telomeropathy: Case Series and Literature Review.

Lebeer M, Wuyts WA, Cassiman D, Laleman W, Nevens F, Pirenne J, Monbaliu D, Roskams T, Verbeken EK, Neyrinck AP, Van Raemdonck DE, Verleden GM, Vos R.

Transplantation. 2018 Oct;102(10):1747-1755. doi: 10.1097/TP.0000000000002198. Review.

PMID:
29596117
29.

Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias.

De Sadeleer LJ, De Langhe E, Bodart N, Vigneron A, Bossuyt X, Wuyts WA.

Lung. 2018 Jun;196(3):329-333. doi: 10.1007/s00408-018-0108-8. Epub 2018 Mar 12.

PMID:
29532165
30.

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, Schwartz DA.

Lancet Respir Med. 2018 Feb;6(2):154-160. doi: 10.1016/S2213-2600(18)30007-9. Review.

31.

Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis.

Wiertz IA, Wuyts WA, van Moorsel CHM, Vorselaars ADM, van Es HW, van Oosterhout MFM, Grutters JC.

Respirology. 2018 Mar;23(3):311-317. doi: 10.1111/resp.13230. Epub 2017 Dec 5.

32.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

33.

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC.

PMID:
28889759
34.

Solid Organ Transplantation in Sarcoidosis.

Yserbyt J, Wuyts WA, Verleden SE, Verleden GM, Van Raemdonck DE, Verbeken EK, Vanaudenaerde BM, Vos R.

Semin Respir Crit Care Med. 2017 Aug;38(4):538-545. doi: 10.1055/s-0037-1602383. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750467
35.

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.

Delanote I, Wuyts WA, Yserbyt J, Verbeken EK, Verleden GM, Vos R.

BMC Pulm Med. 2016 Nov 18;16(1):156.

36.

Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis.

Wuyts WA, Spagnolo P, Bonella F, Yserbyt J, Verleden GM.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1033-1034. No abstract available.

PMID:
27739891
37.

Thin-Section CT Features of Idiopathic Pulmonary Fibrosis Correlated with Micro-CT and Histologic Analysis.

Mai C, Verleden SE, McDonough JE, Willems S, De Wever W, Coolen J, Dubbeldam A, Van Raemdonck DE, Verbeken EK, Verleden GM, Hogg JC, Vanaudenaerde BM, Wuyts WA, Verschakelen JA.

Radiology. 2017 Apr;283(1):252-263. doi: 10.1148/radiol.2016152362. Epub 2016 Oct 6.

38.

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G.

Lung. 2016 Oct;194(5):739-43. doi: 10.1007/s00408-016-9912-1. Epub 2016 Jul 4.

39.

An Important Step Forward, but Still a Way to Go.

Wuyts WA, Bonella F, Costabel U, Cottin V, Kreuter M, Poletti V, Spagnolo P.

Am J Respir Crit Care Med. 2016 Feb 1;193(3):340-1. doi: 10.1164/rccm.201509-1763LE. No abstract available.

PMID:
26829426
40.

Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: More than a Gut Feeling?

Wuyts WA, Collard HR.

Respiration. 2016;91(1):1-2. doi: 10.1159/000443183. Epub 2016 Jan 5. No abstract available.

41.

CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients.

Vercauteren IM, Verleden SE, McDonough JE, Vandermeulen E, Ruttens D, Lammertyn EJ, Bellon H, De Dycker E, Dooms C, Yserbyt J, Verleden GM, Vanaudenaerde BM, Wuyts WA.

Exp Lung Res. 2015;41(8):459-65. doi: 10.3109/01902148.2015.1073407.

PMID:
26381718
42.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.

Wijsenbeek MS, Grutters JC, Wuyts WA.

Adv Ther. 2015 Jul;32(7):691-704. doi: 10.1007/s12325-015-0225-1. Epub 2015 Jul 15.

43.

Linking clinical phenotypes of chronic lung allograft dysfunction to changes in lung structure.

Verleden SE, Vasilescu DM, McDonough JE, Ruttens D, Vos R, Vandermeulen E, Bellon H, Geenens R, Verbeken EK, Verschakelen J, Van Raemdonck DE, Wuyts WA, Sokolow Y, Knoop C, Cooper JD, Hogg JC, Verleden GM, Vanaudenaerde BM.

Eur Respir J. 2015 Nov;46(5):1430-9. doi: 10.1183/09031936.00010615. Epub 2015 Jun 25.

44.

Mechanic's hands in a woman with undifferentiated connective tissue disease and interstitial lung disease--anti-PL7 positive antisynthetase syndrome: a case report.

De Langhe E, Lenaerts J, Bossuyt X, Westhovens R, Wuyts WA.

J Med Case Rep. 2015 Apr 15;9:82. doi: 10.1186/s13256-015-0571-2.

45.

Acquired haemophilia A in a patient with systemic sclerosis treated with autologous haematopoietic stem cell transplantation.

De Langhe E, Lenaerts J, Dierickx D, Hendrickx P, Verleden GM, Wuyts WA, Peerlinck K, Westhovens R.

Rheumatology (Oxford). 2015 Jan;54(1):196-7. doi: 10.1093/rheumatology/keu402. Epub 2014 Oct 6. No abstract available.

PMID:
25525129
46.

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

Wuyts WA, Antoniou KM, Borensztajn K, Costabel U, Cottin V, Crestani B, Grutters JC, Maher TM, Poletti V, Richeldi L, Vancheri C, Wells AU.

Lancet Respir Med. 2014 Nov;2(11):933-942. doi: 10.1016/S2213-2600(14)70232-2. Epub 2014 Nov 3. Review. Erratum in: Lancet Respir Med. 2015 Jan;3(1):e2.

PMID:
25439569
47.

Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort.

Ameye H, Ruttens D, Benveniste O, Verleden GM, Wuyts WA.

Transplant Proc. 2014 Nov;46(9):3147-53. doi: 10.1016/j.transproceed.2014.09.163.

PMID:
25420846
48.

Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?

Wuyts WA, Cavazza A, Rossi G, Bonella F, Sverzellati N, Spagnolo P.

Eur Respir Rev. 2014 Sep;23(133):308-19. doi: 10.1183/09059180.00004914. Erratum in: Eur Respir Rev. 2014 Dec 23(134):537.

49.

Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models.

Wuyts WA, Peccatori FA, Russell AM.

Eur Respir Rev. 2014 Jun;23(132):231-8. doi: 10.1183/09059180.00001614. Review.

50.

Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time.

Spagnolo P, Luppi F, Maher TM, Wuyts WA, Grutters JC.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1271-2. doi: 10.1164/rccm.201209-1755LE. No abstract available.

PMID:
23725621

Supplemental Content

Loading ...
Support Center